Kubota Yoshiaki, Shimizu Wataru
Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
JACC Asia. 2022 Jun 7;2(3):287-293. doi: 10.1016/j.jacasi.2022.03.009. eCollection 2022 Jun.
In addition to showing antidiabetic effects, sodium-glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, including reduced rehospitalization in patients with heart failure, regardless of the presence of diabetes. A recent report showed that the benefits of SGLT2 inhibitors in terms of cardiovascular deaths/admissions caused by heart failure and reduced ejection fraction were greater in Asians than in Whites. In this review, the first part demonstrates the results of recent clinical trials and their clinical implications and outlines current trials and upcoming research areas. The second part provides a general overview of the current understanding of the mechanisms of the cardiovascular benefits of SGLT2 inhibitors.
除了具有抗糖尿病作用外，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂还可降低2型糖尿病患者的心血管事件风险。在心血管结局的主要试验中，SGLT2抑制剂已被证明可改善心血管和肾脏结局，包括降低心力衰竭患者的再次住院率，无论患者是否患有糖尿病。最近的一份报告显示，SGLT2抑制剂在因心力衰竭导致的心血管死亡/住院以及降低射血分数方面对亚洲人的益处大于对白人的益处。在本综述中，第一部分展示了近期临床试验的结果及其临床意义，并概述了当前的试验和即将开展的研究领域。第二部分对目前对SGLT2抑制剂心血管益处机制的理解进行了总体概述。
